Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Phase III Randomized Study

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2008 by All India Institute of Medical Sciences, New Delhi.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
All India Institute of Medical Sciences, New Delhi
ClinicalTrials.gov Identifier:
NCT00715286
First received: July 14, 2008
Last updated: NA
Last verified: July 2008
History: No changes posted

July 14, 2008
July 14, 2008
November 2001
April 2007   (final data collection date for primary outcome measure)
to compare the optimal debulking rate in primary surgery group and neoadjuvant chemotherapy group [ Time Frame: post surgery ] [ Designated as safety issue: Yes ]
Same as current
No Changes Posted
post operative morbidity [ Time Frame: 3 weeks post op ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Phase III Randomized Study
Neoadjuvant Chemotherapy (NACT) Followed by Interval Debulking Surgery vs Upfront Surgery Followed by Chemotherapy (CT) in Advanced Epithelial Ovarian Carcinoma (EOC): A Prospective Randomized Study

To determine the impact of Neoadjuvant chemotherapy on surgical debulking rate, overall and disease-free survival and quality of life (QOL) in patients with advanced EOC.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Ovarian Carcinoma
  • Other: timing of surgery
    Surgery is followed by chemotherapy
  • Other: timing of surgery
    Chemotherapy is followed by surgery
  • Active Comparator: A
    Conventional arm: primary surgery followed by chemotherapy
    Intervention: Other: timing of surgery
  • Experimental: B
    Neoadjuvant chemotherapy followed by interval debulking
    Intervention: Other: timing of surgery
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
180
June 2009
April 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age:20 to 65 years
  • Epithelial ovarian carcinoma
  • Stage IIIc & IV (pleural effusion only)
  • ECOG PS 0-2
  • Cytology/biopsy positive patients
  • Good compliance
  • Previously untreated patients

Exclusion Criteria:

  • Any medical contraindication of surgery
  • Psychiatric illness
  • Cardiac, liver or renal dysfunction
Female
20 Years to 65 Years
No
Contact: Lalit Kumar, DM 91-11-26593405 lalitaiims@yahoo.com
India
 
NCT00715286
I473
Yes
Prof Lalit Kumar, All India Institute of Medical Sciences
All India Institute of Medical Sciences, New Delhi
Not Provided
Principal Investigator: Lalit Kumar, DM All India Institute of Medical Sciences, New Delhi
All India Institute of Medical Sciences, New Delhi
July 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP